Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer Feb 24, 2026 Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Jan 6, 2026 Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer Dec 18, 2025 Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic Oct 3, 2025
Cartography Biosciences Doses First Patient in Phase 1 Trial of CBI-1214, a Highly Specific T-Cell Engager for the Treatment of Colorectal Cancer Feb 24, 2026
Cartography Biosciences and Pfizer to Collaborate on the Discovery of Tumor-Selective Antigens Jan 6, 2026
Cartography Receives FDA Investigational New Drug (IND) Approval and Fast Track Designation for Lead Program CBI-1214 for Colorectal Cancer Dec 18, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic Oct 3, 2025
